QNCX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Quince Therapeutics Inc (QNCX) is not a good buy for a beginner investor with a long-term strategy. The company's core value driver has been removed following the failure of its Phase 3 trial, and analysts have significantly downgraded the stock, with some assigning a price target of zero. The technical indicators, options data, and financial performance do not support a positive outlook, and there are no positive catalysts or trading signals to justify an investment.
The MACD is slightly positive but contracting, indicating weakening momentum. The RSI is neutral at 42.562, showing no clear trend. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading below key pivot levels, with support at 0.084 and resistance at 0.108. Overall, the technical outlook is bearish.
NULL identified. No recent news or events suggest a positive outlook for the stock.
The failure of the Phase 3 NEAT clinical trial has led to the discontinuation of the company's core program. Analysts have downgraded the stock significantly, with one firm assigning a price target of zero. The company's financials show no revenue and significant losses, and the stock is expected to trade near or below cash levels.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$13.44M (up 144.76% YoY), and an EPS of -0.25 (up 92.31% YoY). Gross margin remains at 0%. The financials indicate a struggling company with no clear path to profitability.
Analysts have downgraded the stock heavily following the Phase 3 trial failure. D. Boral Capital, Maxim, Lucid Capital, and Citizens have all reduced their ratings, with Lucid assigning a price target of zero. The consensus view is that the stock has no value and is fully impaired.
